Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.
J Asthma 2019; :1-6JA

Abstract

Background:

The interleukin 5 (IL-5) pathway is an important component in the pathophysiology of severe eosinophilic asthma. Mepolizumab is a monoclonal antibody that targets the IL-5 pathway. Clinical trials showed efficacy of Mepolizumab in patients with severe eosinophilic asthma. However, reports on experience with treatment in a real-world cohort are limited.

Objectives:

Evaluation of the efficacy and safety of Mepolizumab for treatment of severe eosinophilic asthma in a real-world cohort of patients.

Methods:

A clinical prospective observational trial included all patients >18 years treated with Mepolizumab between March 2016 to March 2019 at Rabin Medical Center. The composite primary outcome measures evaluated: increase in FEV1 by≥ 200 ml and/or decrease in exacerbation rate of ≥50% and/or cessation of oral corticosteroids (OCS) treatment or ≥50% decrease in dosage. Also evaluated: blood eosinophil count, adverse events and quality of life.

Results:

Of 61 patients, 50 (82.0%) achieved the primary outcome. The number of patients who suffered from frequent exacerbations decreased from 52 (85.2%) to 8 (13.1%) (p < 0.001). Twenty-two patients (68%) stopped OCS treatment or received >50% reduced dosage (p < 0.001). Mean FEV1 increased from 1.72 ± 0.78 liters to 1.87 ± 0.85 liters (p = 0.043). Response to therapy was seen within six months. Forty-nine patients (80%) reported an improvement in quality of life (p < 0.001). Only minor adverse events were reported.

Conclusion:

Treatment with mepolizumab was well tolerated and significantly lowered the exacerbation rate and OCS dependence in a real-world cohort of severe eosinophilic asthma patients. Response to therapy was within six months and treatment effect was sustained over time.

Authors+Show Affiliations

Pulmonary Division, Rabin Medical Center , Petach Tikva , Israel. Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel.Pulmonary Division, Rabin Medical Center , Petach Tikva , Israel. Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel.Pulmonary Division, Rabin Medical Center , Petach Tikva , Israel. Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel.Pulmonary Division, Rabin Medical Center , Petach Tikva , Israel. Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel.Pulmonary Division, Rabin Medical Center , Petach Tikva , Israel. Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel.Pulmonary Division, Rabin Medical Center , Petach Tikva , Israel. Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31479312

Citation

Pertzov, Barak, et al. "Efficacy and Safety of Mepolizumab in a Real-world Cohort of Patients With Severe Eosinophilic Asthma." The Journal of Asthma : Official Journal of the Association for the Care of Asthma, 2019, pp. 1-6.
Pertzov B, Unterman A, Shtraichman O, et al. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. J Asthma. 2019.
Pertzov, B., Unterman, A., Shtraichman, O., Shitenberg, D., Rosengarten, D., & Kramer, M. R. (2019). Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. The Journal of Asthma : Official Journal of the Association for the Care of Asthma, pp. 1-6. doi:10.1080/02770903.2019.1658208.
Pertzov B, et al. Efficacy and Safety of Mepolizumab in a Real-world Cohort of Patients With Severe Eosinophilic Asthma. J Asthma. 2019 09 3;1-6. PubMed PMID: 31479312.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. AU - Pertzov,Barak, AU - Unterman,Avraham, AU - Shtraichman,Osnat, AU - Shitenberg,Dorit, AU - Rosengarten,Dror, AU - Kramer,Mordechai Reuven, Y1 - 2019/09/03/ PY - 2019/9/4/entrez PY - 2019/9/4/pubmed PY - 2019/9/4/medline KW - Severe asthma KW - anti-IL 5 KW - efficacy KW - eosinophilic asthma KW - mepolizumab SP - 1 EP - 6 JF - The Journal of asthma : official journal of the Association for the Care of Asthma JO - J Asthma N2 - Background: The interleukin 5 (IL-5) pathway is an important component in the pathophysiology of severe eosinophilic asthma. Mepolizumab is a monoclonal antibody that targets the IL-5 pathway. Clinical trials showed efficacy of Mepolizumab in patients with severe eosinophilic asthma. However, reports on experience with treatment in a real-world cohort are limited. Objectives: Evaluation of the efficacy and safety of Mepolizumab for treatment of severe eosinophilic asthma in a real-world cohort of patients. Methods: A clinical prospective observational trial included all patients >18 years treated with Mepolizumab between March 2016 to March 2019 at Rabin Medical Center. The composite primary outcome measures evaluated: increase in FEV1 by≥ 200 ml and/or decrease in exacerbation rate of ≥50% and/or cessation of oral corticosteroids (OCS) treatment or ≥50% decrease in dosage. Also evaluated: blood eosinophil count, adverse events and quality of life. Results: Of 61 patients, 50 (82.0%) achieved the primary outcome. The number of patients who suffered from frequent exacerbations decreased from 52 (85.2%) to 8 (13.1%) (p < 0.001). Twenty-two patients (68%) stopped OCS treatment or received >50% reduced dosage (p < 0.001). Mean FEV1 increased from 1.72 ± 0.78 liters to 1.87 ± 0.85 liters (p = 0.043). Response to therapy was seen within six months. Forty-nine patients (80%) reported an improvement in quality of life (p < 0.001). Only minor adverse events were reported. Conclusion: Treatment with mepolizumab was well tolerated and significantly lowered the exacerbation rate and OCS dependence in a real-world cohort of severe eosinophilic asthma patients. Response to therapy was within six months and treatment effect was sustained over time. SN - 1532-4303 UR - https://www.unboundmedicine.com/medline/citation/31479312/Efficacy_and_safety_of_mepolizumab_in_a_real-world_cohort_of_patients_with_severe_eosinophilic_asthma L2 - http://www.tandfonline.com/doi/full/10.1080/02770903.2019.1658208 DB - PRIME DP - Unbound Medicine ER -